Becton, Dickinson and Company BDX BioPharma Systems — Selling and administrative expense

Other segment segments

Similar metrics at other companies

PFEBiopharma — Selling, informational and administrative expenses

$2.13B-2.5%

TMOLaboratory Products and Biopharma Services — Selling, general and administrative expenses

$597M+1.5%

IFFHealth & Biosciences — Selling and administrative expenses

$92M+13.6%

BAXPharmaceuticals — Selling, general and administrative expenses

$102M-1.0%

BLCOPharmaceuticals — Selling, general and administrative (Note 4)

$138M-9.8%

TMOLife Sciences Solutions — Selling, general and administrative expenses

$496M+6.0%

Questions, answered.

What is Becton, Dickinson and Company's biopharma systems — selling and administrative expense?

Becton, Dickinson and Company (BDX) reported biopharma systems — selling and administrative expense of $32M in Q1 2026.

What does biopharma systems — selling and administrative expense mean?

This metric captures the operating expenses related to the sales, marketing, and general administrative functions specifically allocated to the BioPharma Systems segment. It reflects the overhead required to support the commercialization and management of the segment's product portfolio.